[go: up one dir, main page]

WO1995005173A1 - Compositions orales contenant des antagonistes de h¿2? - Google Patents

Compositions orales contenant des antagonistes de h¿2? Download PDF

Info

Publication number
WO1995005173A1
WO1995005173A1 PCT/US1994/009204 US9409204W WO9505173A1 WO 1995005173 A1 WO1995005173 A1 WO 1995005173A1 US 9409204 W US9409204 W US 9409204W WO 9505173 A1 WO9505173 A1 WO 9505173A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
calcium carbonate
antagonist
weight
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1994/009204
Other languages
English (en)
Inventor
Henry C. Caldwell
Ashok J. Desai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AAIPharma Inc
Original Assignee
Applied Analytical Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Analytical Industries Inc filed Critical Applied Analytical Industries Inc
Priority to JP7507128A priority Critical patent/JPH09501680A/ja
Priority to AU75655/94A priority patent/AU7565594A/en
Priority to EP94925883A priority patent/EP0715516A1/fr
Publication of WO1995005173A1 publication Critical patent/WO1995005173A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds

Definitions

  • This invention relates to pharmaceutically elegant compositions of therapeutic compounds having H 2 -antagonist activity especially adapted for convenient oral administration.
  • U.S. Patent No. 4,719,228 discloses the use of selected synthetic silicas to form free flowing powder products of a number of therapeutic classes of drugs including antiulcer drugs. No reference to H 2 - antagonists is made here.
  • This invention relates to pharmaceutical oral compositions containing one or more H 2 -antagonist drugs. These compositions do not exhibit a bitter taste in the mouth and distribute the active ingredient substantially in the gastrointestinal tract.
  • the composition contains, as essential ingredients, an H 2 -antagonist - magnesium aluminum silicate complex and calcium carbonate.
  • the dosage unit form is any which would normally expose the bitter H 2 -antagonist to the taste of the patient but is preferably a chewable tablet. For larger doses, it may be a sachet, lozenge or packaged flavored granules. Best Mode for Carrying Out the Invention
  • H 2 -compounds are preferably administered orally.
  • the oral product forms of these compounds are capsules or coated tablets. Certain segments of the patient population prefer more easily ingested product forms. This is most evident in the over- the-counter market.
  • One of the most useful of such product forms is the chewable or frangible tablet, lozenge or troche. Examples of the preparation of chewable products are found in U.S. Patent No. 4,711,774 which is cited in the Background section above.
  • H 2 -antagonists form tasteless adsorbates with magnesium aluminum silicate readily and substantially completely.
  • the addition of a selected quantity of calcium carbonate dramatically improves the release of active ingredient from the silicate adsorbate, but does not cause overt side effects such as substantial release of carbon dioxide by effervescence. This is so especially when the formulations are prepared with acid addition salts of the biologically active ingredients or with added solid acid formulation aids such as the fruit acids, for example citric acid, within the granules in the formulation process.
  • the complex between the active biological ingredient and the magnesium aluminum silicate is usually formed in situ, that is, during the formulation of the dosage unit composition.
  • composition of this invention is in its preferred form a chewable tablet comprised essentially of a therapeutically effective but non-toxic dosage unit quantity of an H 2 -antagonist complex formed with a magnesium aluminum silicate, which complex is usually prepared during formulation, and a quantity of calcium carbonate.
  • the magnesium aluminum silicate which is the support component of this combination is preferably the commercial product known as "Veegum” supplied by R.T. Vanderbilt Company, Inc. Analysis of the commercial product is carried out as oxide contents. No control of the particle size of the commercial grade of product has been found necessary. Comprehensive descriptions of the product are in the Zentner-Denick patents noted above.
  • the exact quantity of the silicate support is not critical to the invention as long as enough is present to completely adsorb the drug component in situ. An excess is most convenient and preferred with ranges of from 10 - 30% by weight of the dosage unit.
  • Magnesium aluminum silicates have been used in the literature to delay the release of other active ingredients in time release products when used in excess. This is in contrast to the present invention which affords good quick release of drug.
  • the H 2 -antagonist in either the base or its acid addition salt form as appropriate, is preferably selected from those approved for use in either the prescription or over-the-counter pharmaceutical markets.
  • the dosage units will contain either a full therapeutic dose, or a partial dose for a subject in need of relief so that from 1-5 units may be administered per day to obtain satisfactory treatment of symptoms.
  • the non-prescription products usually contain a lower dose, often about half the quantity.
  • active H 2 -antagonists examples include cimetidine (300 mg) , nizatidine (150 mg) , roxatidine (acetate), famotidine (20 mg) , ranitidine (150 mg) , tiotidine, lamtidine, mifentidine, zaltidine, KV-1257 or loxtidine (Handbook Exp. Pharmacol. 97 573-748 (1991), "Histamine and Histamine Antagonists”) .
  • the daily dose range of active ingredient is a nontoxic but H 2 -antagonist effective quantity and may be chosen from 40 to 1600 mg.
  • the dosage units may range from 10 - 800 mg of active ingredient depending on the known individual activity and market of the H 2 -antagonist drug.
  • the units are administered from 1-5 times daily orally to a patient in need of H 2 -antagonist treatment.
  • the H 2 -antagonist may be present either as the base if appropriate or as a salt thereof with a nontoxic, pharmaceutically acceptable acid.
  • the dose and the form which is commercially available is conveniently used.
  • the H 2 -antagonist-silicate adsorbate is formed substantially completely during formulation despite which base or salt form of the active H 2 -antagonist is selected.
  • the calcium carbonate is selected from the range of 75-500 mg per dosage unit.
  • the calcium carbonate supplemented product is preferably used in non-toxic quantities in up to 5 units per day.
  • a general range of calcium carbonate content of the oral product is from about 1-35% by weight of the chewable tablet products. For example, for a 1500 mg. tablet as much as 500 mg. of calcium carbonate may be present. Overt evolution of carbon dioxide has not been observed when the compositions contact water.
  • One skilled in the art will recognize that the size of chewable tablets may be larger than that of normal compressed tablets.
  • composition of this invention may be optionally used in addition to the essential ingredients described above.
  • these are bulking agents, flavoring agents. granulating agents, buffering agents, coloring agents, preservatives, confectioneries and the like. Reference may be made to U.S. Patent No. 4,711,774 for more specific formulation information.
  • Especially useful optional ingredients are the solid fruit acids such as citric, malic or tartaric acids in up to 3% by weight for good stability and palatability of the chewable tablet as well as xylitol or mannitol as a sweetening-bulking agent in up to 70% by weight.
  • Citric acid as well as xylitol are particularly advantageous since each contributes unexpectedly well to the palatability of the chewable tablets.
  • quantity of calcium carbonate and acid should be selected to insure good release, but not to cause overt carbon dioxide evolution. The absence of the acid component gives acceptable products as well.
  • the chewable tablets of this invention are prepared by mixing the H 2 -antagonist compound with magnesium aluminum silicate in a weight ratio chosen from the range of 1 to 1 down to 1 to 10 with an optional sweetening agent in a mixer, adding water to form the complex and granulate.
  • the dried and milled granules are mixed with the calcium carbonate, bulking-sweetening agents and tabletting aids then compressed into tablets.
  • the chewable pharmaceutical products are taken by the subject in need of H 2 -antagonist treatment orally from 1 to 5 times daily as required to satisfy the acceptable daily dosage regimen of active ingredients. It should be particularly noted that the antacid component of the chewable tablet may also contribute to lowering the acid content of the gastrointestinal tract.
  • the dosage units should be prepared and used with this in mind.
  • the method of analysis used and detailed hereafter is the ultraviolet dissolution method as reported in the USP XXII (p. 3074) . Usually times for pulling samples were 15, 30, 45, 60 minutes. The ultraviolet wave lengths vary, of course, with the active ingredient. Cimetidine is at 218 nm. Nizatidine and ranitidine are at 314 nm. Famotidine is at 265 nm.
  • an acid agent such as a fruit acid, for example, citric, malic or tartaric acid in the formulation, this is added to the manufacturing process at Step 1 before the granulation • process, usually at about 1.5%.
  • Example 3 The percentage of cimetidine dissolved in water using the U.S.P. method II at 50 RPM to 60 minutes from granules with added citric acid (3%), calcium carbonate (75 mg) and without calcium carbonate. Time Without CaC0 3 With CaC0 3
  • Example 5 Nizatidine with and without calcium carbonate compared at 0 time and 1 month stability (40°; 75%RH) , citric acid (1.5%) added to all samples.
  • Nizatidine granules compared in water with tablet with 1.5% citric acid and tablet with 1.5% of citric acid and 37.5 mg of calcium carbonate.
  • Example 1 The process of Example 1 is used with 25% by weight of magnesium aluminum silicate, 5% of nizatidine, 0.25% of sodium saccharin and 1.2% of citric acid. The granules, before tabletting, were compared with the tabletted product and with the chewable tablet with 5% of calcium carbonate.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Comprimés à mâcher d'antagonistes de H2 qui n'ont pas de goût dans la bouche, mais permettent une bonne libération des ingrédients actifs. Lesdits comprimés sont préparés à l'aide de carbonate de calcium et d'un silicate de magnésium-aluminium en tant que support. Ils contiennent également des ingrédients non essentiels tels que du xylitol et des acides de fruits.
PCT/US1994/009204 1993-08-17 1994-08-16 Compositions orales contenant des antagonistes de h¿2? Ceased WO1995005173A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP7507128A JPH09501680A (ja) 1993-08-17 1994-08-16 Ｈ▲下２▼−アンタゴニストの経口組成物
AU75655/94A AU7565594A (en) 1993-08-17 1994-08-16 Oral compositions of h2-antagonists
EP94925883A EP0715516A1 (fr) 1993-08-17 1994-08-16 Compositions orales contenant des antagonistes de h 2?

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10712693A 1993-08-17 1993-08-17
US08/107,126 1993-08-17
US28871194A 1994-08-12 1994-08-12
US08/288,711 1994-08-12

Publications (1)

Publication Number Publication Date
WO1995005173A1 true WO1995005173A1 (fr) 1995-02-23

Family

ID=26804421

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/009204 Ceased WO1995005173A1 (fr) 1993-08-17 1994-08-16 Compositions orales contenant des antagonistes de h¿2?

Country Status (5)

Country Link
EP (1) EP0715516A1 (fr)
JP (1) JPH09501680A (fr)
AU (1) AU7565594A (fr)
CA (1) CA2169735A1 (fr)
WO (1) WO1995005173A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996023494A1 (fr) * 1995-02-02 1996-08-08 Applied Analytical Industries, Inc. Compositions orales d'antagonistes de h¿2?
US6537525B1 (en) * 1997-01-29 2003-03-25 Douglas H. West Medicated chewing-gum
US7204265B2 (en) 2002-02-13 2007-04-17 Zimmer Aktiengesellschaft Bursting insert
US7364681B2 (en) 2002-01-08 2008-04-29 Stefan Zikeli Spinning device and method having cooling by blowing
WO2007108010A3 (fr) * 2006-03-21 2008-05-22 Jubilant Organosys Ltd Composition pharmaceutique à goût masque pour forme dosifiée orale solide et son procédé de préparation
US7614864B2 (en) 2002-01-28 2009-11-10 Stefan Zikeli Ergonomic spinning system
US10874541B2 (en) 2017-11-09 2020-12-29 11 Health And Technologies Limited Ostomy monitoring system and method

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992017164A1 (fr) * 1991-04-04 1992-10-15 The Procter & Gamble Company Compositions pharmaceutiques administrees par voie buccale dans le traitement de troubles de la partie superieure des voies gastro-intestinales
US5229137A (en) * 1992-05-06 1993-07-20 Brigham And Women's Hospital, Inc. Methods and pharmaceutical compositions for treating episodic heartburn

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992017164A1 (fr) * 1991-04-04 1992-10-15 The Procter & Gamble Company Compositions pharmaceutiques administrees par voie buccale dans le traitement de troubles de la partie superieure des voies gastro-intestinales
US5229137A (en) * 1992-05-06 1993-07-20 Brigham And Women's Hospital, Inc. Methods and pharmaceutical compositions for treating episodic heartburn

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996023494A1 (fr) * 1995-02-02 1996-08-08 Applied Analytical Industries, Inc. Compositions orales d'antagonistes de h¿2?
US6537525B1 (en) * 1997-01-29 2003-03-25 Douglas H. West Medicated chewing-gum
US7364681B2 (en) 2002-01-08 2008-04-29 Stefan Zikeli Spinning device and method having cooling by blowing
US7614864B2 (en) 2002-01-28 2009-11-10 Stefan Zikeli Ergonomic spinning system
US7204265B2 (en) 2002-02-13 2007-04-17 Zimmer Aktiengesellschaft Bursting insert
WO2007108010A3 (fr) * 2006-03-21 2008-05-22 Jubilant Organosys Ltd Composition pharmaceutique à goût masque pour forme dosifiée orale solide et son procédé de préparation
US10874541B2 (en) 2017-11-09 2020-12-29 11 Health And Technologies Limited Ostomy monitoring system and method

Also Published As

Publication number Publication date
AU7565594A (en) 1995-03-14
CA2169735A1 (fr) 1995-02-23
EP0715516A1 (fr) 1996-06-12
JPH09501680A (ja) 1997-02-18

Similar Documents

Publication Publication Date Title
AU681672B2 (en) Preparations containing silicon dioxide to improve the taste thereof
US5225197A (en) Pharmaceutical formulation
EP0664697B1 (fr) Comprimes de ranitidine a mastiquer
EP0349103B1 (fr) Comprimé à mâcher
IE61692B1 (en) Pharmaceutical compositions
US6024987A (en) Pharmaceutical, orally applicable composition
EP1566174A2 (fr) Forme de dosage orale très fondante
JPH05112445A (ja) 作用開始を速くし潜在特性を増加させる移送システム
US20070122475A1 (en) Taste masking composition
US5622980A (en) Oral compositions of H2-antagonists
EP0715516A1 (fr) Compositions orales contenant des antagonistes de h 2?
WO1996004888A1 (fr) Compositions d'antagonistes h2 s'administrant par voie orale
JPH07165590A (ja) 医薬組成物
IL105870A (en) Pharmaceutical soft capsules containing lysine clonixinate and their preparation
HK1004522B (en) Pharmaceutical formulation
CN1140996A (zh) 雷尼替丁和碳酸钙药物复合品
EP0574624A1 (fr) Compositions pharmaceutiques
HK1074009A (en) Flash-melt oral dosage formulation
HK1010687B (en) Film coated tablet of paracetamol and domperidone
HK1010687A1 (en) Film coated tablet of paracetamol and domperidone
AU2138095A (en) Low dosage ranitidine compositions for the treatment of minor gastrointestinal disorders associated with excess acid secretion

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KP KR KZ LK LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2169735

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1994925883

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1994925883

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994925883

Country of ref document: EP